Coexisting Germline CHEK2 and Somatic BRAF(V600E) Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course

Lignende værker

• Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma
  af: Szymonek, Monika, et al.
  Udgivet: (2017)
• Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma
  af: Gąsior-Perczak, Danuta, et al.
  Udgivet: (2021)
• The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer
  af: Kowalska, Aldona, et al.
  Udgivet: (2015)
• The p.G534E variant of HABP2 is not associated with sporadic papillary thyroid carcinoma in a Polish population
  af: Kowalik, Artur, et al.
  Udgivet: (2017)
• Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications
  af: Kowalik, Artur, et al.
  Udgivet: (2017)